Humira Humira
Stories About

Humira

A new precision medicine test could help doctors and patients zero in on the right arthritis drug much sooner. But insurance coverage and drug company incentives are hurdles to widespread use. Adam Gault/SPL/Getty Images hide caption

toggle caption
Adam Gault/SPL/Getty Images

AbbVie's Humira was the world's best-selling drug for many years. Now it faces competition for copycats that cost a fraction of its price. David J. Phillip/AP hide caption

toggle caption
David J. Phillip/AP

Blockbuster drug Humira finally faces lower-cost rivals

  • Download
  • <iframe src="https://www.npr.org/player/embed/1188745297/1188780602" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Humira, the injectable biologic treatment for rheumatoid arthritis, now faces its first competition from one of several copycat "biosimilar" drugs expected to come to market this year. Some patients spend $70,000 a year on Humira. JB Reed/Bloomberg via Getty Images hide caption

toggle caption
JB Reed/Bloomberg via Getty Images